Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 8Recruiting 3Active not recruiting 3Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 12Rectal Neoplasms 7Colonic Neoplasms 5Pancreatic Neoplasms 3Stomach Neoplasms 2Glioblastoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumor Malignancy 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Pediatric Solid Tumors 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lung Neoplasms 1Gliosarcoma 1Gallbladder Neoplasms 1Colorectal Adenocarcinoma Metastatic to the Liver 1Central Nervous System Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1Astrocytoma 1

Interventions

selinexor 1liposomal doxorubicin 1ixazomib 1fludarabine phosphate 1Temozolomide 1PM 01183 1Melphalan 1Irinotecan 1Erlotinib Hydrochloride 1Electroacupuncture 1Busulfan 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Sarcoma, Ewing × Irinotecan × Clear all
NCT05042934 2022-02-10

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡